Viewpoint: a proposal for a simple algorithm for managing oral anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation and coronary stents

European Heart Journal: Acute Cardiovascular Care

Volumn 6, Issue 1, 2017, Pages 93-97

  Steg, Ph Gabriel ^a,b,c,d   Bhatt, Deepak L ^e  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Site Xavier Bichat and Département Hospitalo Universitaire Fibrosis Inflammation and Remodeling   (France)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; CLOPIDOGREL; DABIGATRAN; EDOXABAN; PROTON PUMP INHIBITOR; PURINERGIC P2Y12 RECEPTOR; TICLOPIDINE; ANTICOAGULANT AGENT;

ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; BARE METAL STENT; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); CORONARY STENT; DRUG ELUTING STENT; DRUG WITHDRAWAL; DUAL ANTIPLATELET THERAPY; HUMAN; LOW DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; STENT THROMBOSIS; ADVERSE EFFECTS; ALGORITHM; CLINICAL STUDY; DISEASE MANAGEMENT; ORAL DRUG ADMINISTRATION; STENT;

ADMINISTRATION, ORAL; ALGORITHMS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CLINICAL STUDIES AS TOPIC; DISEASE MANAGEMENT; HUMANS; PLATELET AGGREGATION INHIBITORS; STENTS;

EID: 85050576981     PISSN: 20488726     EISSN: 20488734     Source Type: Journal    
DOI: 10.1177/2048872615610868     Document Type: Article

References (23)

1. Lip GY, Windecker S, Huber K. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014; 35: 3155–3179.
2. Faxon DP, Eikelboom JW, Berger PB. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011; 106: 572–584.
3. Ruff CT, Giugliano RP, Braunwald E. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955–962.
4. Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013; 368: 1272–1274.
5. Qamar A, Bhatt DL. Balancing the risks of stroke and bleeding in CKD. Nat Rev Nephrol 2015; 11: 200–202.
6. Gibson CM, Mehran R, Bode C. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J 2015; 169: 472–478 e5.
7. The CURRENT-OASIS 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010; 363: 930–942.
8. Lamberts M, Gislason GH, Olesen JB. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol 2013; 62: 981–989.
9. Sorensen R, Hansen ML, Abildstrom SZ. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009; 374: 1967–1974.
10. Dewilde WJ, Oirbans T, Verheugt FW. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381: 1107–1115.
11. Hamm CW, Bassand JP, Agewall S. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999–3054.
12. Anderson JL, Adams CD, Antman EM. American College of Cardiology Foundation/American Heart Association Task Force on Practice G. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127: e663–e828.
13. Steg PG, James SK, Atar D. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569–2619.
14. O’Gara PT, Kushner FG, Ascheim DD. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127: 529–555.
15. Wiviott SD, Steg PG. Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet 2015; 386: 292–302.
16. Fiedler KA, Maeng M, Mehilli J. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation. The ISAR-TRIPLE Trial. J Am Coll Cardiol 2015; 65: 1619–1629.
17. Bhatt DL. When is a double better than a TRIPLE? Stenting in patients with atrial fibrillation. J Am Coll Cardiol 2015;65:1630–1632.
18. Sabate M, Cequier A, Iniguez A. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet 2012; 380: 1482–1490.
19. Bhatt DL. Examination of new drug-eluting stents–top of the class! Lancet 2012; 380: 1453–1455.
20. Palmerini T, Sangiorgi D, Valgimigli M. Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis. J Am Coll Cardiol 2015; 65: 1092–1102.
21. Mauri L, Kereiakes DJ, Yeh RW. DAPT Study Investigators.Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371: 2155–2166.
22. Yeh RW, Kereiakes DJ, Steg PG. DAPT Study Investigators.Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. J Am Coll Cardiol. 2015; 65: 2211–2221.
23. Udell JA, Bonaca MP, Collet JP. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J 2015; Aug 31, e-pub ahead of print.